Published in PLoS One on June 07, 2012
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Replicating genotype-phenotype associations. Nature (2007) 16.11
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 11.62
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2006) 3.73
ESPERR: learning strong and weak signals in genomic sequence alignments to identify functional elements. Genome Res (2006) 2.65
Small insertions and deletions (INDELs) in human genomes. Hum Mol Genet (2010) 2.25
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum (2010) 2.08
Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med (2008) 1.97
The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum (2003) 1.84
Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther (2009) 1.66
The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit Rev Immunol (2004) 1.59
The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum (2004) 1.55
Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis (2003) 1.48
Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum (2003) 1.46
Identification of nine novel loci associated with white blood cell subtypes in a Japanese population. PLoS Genet (2011) 1.45
Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum (2011) 1.44
DANBIO--powerful research database and electronic patient record. Rheumatology (Oxford) (2011) 1.40
Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther (2010) 1.23
Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis (2011) 1.19
The discovery of human genetic variations and their use as disease markers: past, present and future. J Hum Genet (2010) 1.17
Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet (2008) 1.16
Recent development in pharmacogenomics: from candidate genes to genome-wide association studies. Expert Rev Mol Diagn (2007) 1.11
Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. Arthritis Res Ther (2006) 1.07
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis (2010) 1.06
Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr Opin Rheumatol (2008) 1.06
Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis (2008) 1.05
CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clin Exp Immunol (2010) 1.04
Genetic and genomic predictors of anti-TNF response. Pharmacogenomics (2011) 1.02
Amisyn, a novel syntaxin-binding protein that may regulate SNARE complex assembly. J Biol Chem (2002) 1.01
The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann Rheum Dis (2008) 1.00
Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J Immunol (2006) 1.00
Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis (2010) 0.96
Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis (2010) 0.93
Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol (2007) 0.91
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics (2009) 0.91
Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Res Ther (2010) 0.89
Decreased collagen-induced arthritis severity and adaptive immunity in MKK-6-deficient mice. Arthritis Rheum (2012) 0.85
The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α-308 G/G promoter polymorphism. Clin Rheumatol (2011) 0.84
Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenet Genomics (2010) 0.81
A coalescent simulation of marker selection strategy for candidate gene association studies. Am J Med Genet B Neuropsychiatr Genet (2008) 0.77
Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol (2005) 3.80
Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A (2002) 3.11
A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet (2004) 2.30
Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. Arthritis Rheumatol (2014) 2.06
Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol (2008) 1.90
No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis (2010) 1.89
GENECOUNTING: haplotype analysis with missing genotypes. Bioinformatics (2002) 1.74
Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetic resonance imaging score in a multireader, longitudinal setting. Arthritis Rheum (2005) 1.63
Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis (2010) 1.46
Detection, scoring and volume assessment of bone erosions by ultrasonography in rheumatoid arthritis: comparison with CT. Ann Rheum Dis (2012) 1.44
MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol (2012) 1.43
High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res (2003) 1.42
Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res (2011) 1.41
Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis (2013) 1.39
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol (2007) 1.35
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol (2002) 1.29
Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis (2011) 1.28
Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. J Rheumatol (2011) 1.27
Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann Rheum Dis (2010) 1.25
Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate (2006) 1.24
Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer (2005) 1.22
MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis (2010) 1.19
High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer (2002) 1.18
Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol (2003) 1.18
Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers (2008) 1.18
Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes (2008) 1.14
Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index. World J Surg (2012) 1.14
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J (2009) 1.12
Improving basic and translational science by accounting for litter-to-litter variation in animal models. BMC Neurosci (2013) 1.12
Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum (2013) 1.12
Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci (2005) 1.10
Imaging in rheumatoid arthritis--why MRI and ultrasonography can no longer be ignored. Scand J Rheumatol (2003) 1.10
IL-6, but not TNF-α, increases plasma YKL-40 in human subjects. Cytokine (2011) 1.09
High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep (2003) 1.09
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat Rev Drug Discov (2010) 1.08
Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis (2008) 1.08
Correlation between computer-aided dynamic gadolinium-enhanced MRI assessment of inflammation and semi-quantitative synovitis and bone marrow oedema scores of the wrist in patients with rheumatoid arthritis--a cohort study. Rheumatology (Oxford) (2011) 1.08
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother (2008) 1.07
The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology (Oxford) (2013) 1.07
Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta (2011) 1.07
Established rheumatoid arthritis - new imaging modalities. Best Pract Res Clin Rheumatol (2007) 1.06
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother (2007) 1.05
High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin Cancer Res (2005) 1.04
Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol (2006) 1.04
After treat-to-target: can a targeted ultrasound initiative improve RA outcomes? Ann Rheum Dis (2012) 1.04
Common haplotypes in five genes influence genetic variance of LDL and HDL cholesterol in the general population. Hum Mol Genet (2002) 1.02
Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol (2010) 1.01
Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet Genomics (2009) 1.00
Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand J Infect Dis (2002) 1.00
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol (2009) 1.00
Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFα inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics (2012) 1.00
Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer (2010) 0.99
Peptides modulating conformational changes in secreted chaperones: from in silico design to preclinical proof of concept. Proc Natl Acad Sci U S A (2009) 0.98
Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int (2008) 0.98
Global regulation of alternative splicing by adenosine deaminase acting on RNA (ADAR). RNA (2013) 0.98
YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer (2009) 0.97
Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res (2008) 0.97
Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas (2012) 0.97
Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome. J Rheumatol (2008) 0.97
YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat (2007) 0.96
ViralZone: recent updates to the virus knowledge resource. Nucleic Acids Res (2012) 0.96
OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Exercise 5: an international multicenter reliability study using computerized MRI erosion volume measurements. J Rheumatol (2003) 0.94
The evidence for magnetic resonance imaging as an outcome measure in proof-of-concept rheumatoid arthritis studies. J Rheumatol (2005) 0.94
Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand (2003) 0.93
YKL-40 protein expression in normal adult human tissues--an immunohistochemical study. J Mol Histol (2007) 0.93
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy (2010) 0.93
Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity. J Pharmacol Exp Ther (2010) 0.92
Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford) (2012) 0.92
Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol (2010) 0.92
An open-source, self-explanatory touch screen in routine care. Validity of filling in the Bath measures on Ankylosing Spondylitis Disease Activity Index, Function Index, the Health Assessment Questionnaire and Visual Analogue Scales in comparison with paper versions. Rheumatology (Oxford) (2009) 0.92
Rheumatoid arthritis bone erosion volumes on CT and MRI: reliability and correlations with erosion scores on CT, MRI and radiography. Ann Rheum Dis (2007) 0.91
Large-scale unrestricted identification of post-translation modifications using tandem mass spectrometry. Anal Chem (2007) 0.91
Microanatomic studies to define predictive factors for the topography of periarticular erosion formation in inflammatory arthritis. Arthritis Rheum (2009) 0.91
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol (2009) 0.91
YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol (2009) 0.91
YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers. J Histochem Cytochem (2011) 0.90
High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer (2008) 0.89
The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology (2011) 0.89
Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res (2012) 0.89
High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients. Eur J Haematol (2007) 0.88
Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines. Mol Cancer Ther (2013) 0.87
Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest (2010) 0.87
Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 0.87
After treat-to-target: can a targeted ultrasound initiative improve RA outcomes? Postgrad Med J (2012) 0.87
Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Res Ther (2011) 0.86
Fetal growth and preterm birth in children exposed to maternal or paternal rheumatoid arthritis: a nationwide cohort study. Arthritis Rheumatol (2014) 0.86
Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS One (2013) 0.86